AC Immune (ACIU) Tax Provisions (2022 - 2023)
AC Immune (ACIU) reported Tax Provisions of -$1127.4 for Q4 2023, up 45.7% year-over-year from -$773.77 in Q4 2022, and up 66.81% on a QoQ basis from -$3396.5 in Q3 2023.
AC Immune (ACIU) has 2 years of Tax Provisions data on file, last reported at -$1127.4 in Q4 2023.
- Quarterly Tax Provisions rose 45.7% year-over-year to -$1127.4 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$11103.8 (up 18.74% YoY) and the FY2024 annual result came in at -$3424.6, up 69.62% from the prior year.
- Tax Provisions rose to -$1127.4 in Q4 2023 per ACIU's latest filing, from -$3396.5 in the prior quarter.
- Across five years, Tax Provisions topped out at -$1127.4 in Q4 2023 and bottomed at -$4331.2 in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,127.35 |
| Sep 30, 2023 | -3,396.46 |
| Jun 30, 2023 | -3,336.53 |
| Mar 31, 2023 | -3,243.49 |
| Dec 31, 2022 | -2,076.04 |
| Sep 30, 2022 | -4,141.83 |
| Jun 30, 2022 | -3,114.88 |
| Mar 31, 2022 | -4,331.23 |